Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S, Dimopoulos M, Palumbo A, et al. N Engl J Med, 373:621, Aug 2015

 

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. Lokhorst HM, Plesner T, Laubach JP,et al. N Engl J Med. 2015 Aug 26. [Epub ahead of print]

 

Proteasome inhibitors and immunomodulatory agents have improved survival in multiple myeloma. Now it appears that immunotherapy agents may provide more progress in the treatment of this disease. Elotuzumab (1), a monoclonal antibody targeting signaling lymphocytic activation molecule F7 and daratumumab (2), an antibody directed against CD38, showed encouraging results in patients with relapsed, refractory multiple myeloma. There are many other monoclonal antibodies in ongoing clinical testing.